TECLens Secures Funding for qCXL
TECLens raises $10 Million to advance its non-invasive vision correction platform
Clinical Scorecard: TECLens Secures Funding for qCXL
At a Glance
Category Detail
Condition Refractive Vision Correction Key Mechanisms Quantitative corneal cross-linking (qCXL) using personalized patterns of ultraviolet light. Target Population Patients with refractive errors, particularly presbyopia. Care Setting Clinical-stage medical device development.
Key Highlights
TECLens closed a $10 million Series A2 extension financing. Funding will support clinical development of the qCXL platform. The CXLens System reshapes the cornea without cutting or removing tissue. Ongoing proof-of-concept study evaluating qCXL for refractive vision correction. Guideline-Based Recommendations
Diagnosis
Evaluate patients with refractive errors for potential qCXL treatment. Management
Utilize the CXLens System for non-invasive corneal reshaping. Monitoring & Follow-up
Conduct real-time ultrasound monitoring during treatment. Risks
Consider potential risks associated with new medical device technologies. Patient & Prescribing Data
Individuals with refractive vision errors, especially presbyopia.
Clinical Best Practices
Incorporate individualized treatment planning for qCXL. Monitor patient outcomes during the proof-of-concept study. Related Resources & Content
